ImmunityBio revenue rises 53% as losses and spending expand
ImmunityBio reported $48.7 million in third-quarter product revenue, up 53%, as ANKTIVA adoption expanded. Cash reached $334.3 million, but higher spending widened losses.
Topic
Anktiva
Topic
Anktiva
ImmunityBio Shares Fall 19% on Revenue Miss, Going-Concern Warning
ImmunityBio shares fell 19% to US$6.97 after revenue missed consensus and a US$184.6 million loss widened. ANKTIVA sales rose 53%…
ImmunityBio Shares Jump 10% on Erdogan Meeting
ImmunityBio (IBRX) closed up 9.94% at $9.29 after Dr. Patrick Soon-Shiong met President Erdogan, fueling hopes for the company's…